BetterLife Pharma Inc.: Business Overview, Financials & Competitive Analysis
BetterLife Pharma Inc. is an emerging biotechnology company primarily focused on developing and commercializing BETR-001 to treat various neurological disorders. BETR-001 is a non-hallucinogenic neuroplastogen based o...
Cyborg Score thesis
Early-stage biotech with differentiated lead asset and IP protection targeting large neurological pain markets, but with capital...
Read the full analyst-debate transcript →Get the Latest BetterLife Pharma Inc. Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeBetterLife Pharma Inc. Overview
Pro stress-test →BetterLife Pharma Inc. is an emerging biotechnology company primarily focused on developing and commercializing BETR-001 to treat various neurological disorders. BETR-001 is a non-hallucinogenic neuroplastogen based on 2-bromo-lysergic acid diethylamide (2-bromo-LSD), intended for the treatment of major depressive disorder, anxiety disorder, neuropathic pain, and other neuropsychiatric and neurological conditions. The company operates as an early-stage biotech with a lean team of approximately 7 employees, concentrating resources on clinical advancement.
Strategic Profile
Pro stress-test →BetterLife holds a USPTO composition-of-matter patent on BETR-001, has completed its FDA pre-IND meeting, and has completed most required IND-enabling studies. In June 2026, BetterLife closed a CAD $2,000,000 convertible debenture financing to fund the remaining IND-enabling work on BETR-001, as the company sharpens its focus on neurological pain indications, with an initial emphasis on cluster headache and migraine. The company also maintains interferon-based technologies with potential to engage the immune system to fight viral infections.
Competitive Landscape
Pro stress-test →BetterLife competes in the neuropsychiatric and neurological therapeutics space against established pharma companies and biotech firms developing treatments for depression, anxiety, neuropathic pain, and cluster headache. The non-hallucinogenic LSD-derivative space has attracted increased biotech interest, creating a nascent competitive field. BETR-001's differentiated mechanism (neuroplastogen activity without hallucinations) aims to address unmet needs where traditional SSRIs and other standard therapies show limited efficacy or tolerability.
Industry Context
BetterLife Pharma Inc. operates in Biotechnology.
Key facts
Founded: 2002 · Headquarters: Vancouver, Canada · Employees: 7 · Revenue: Estimated $0 (preclinical/development stage, no approved products) · Market cap: ~$20M-$35M (volatile; $121.81M as of October 2026 per recent market data)